Full-Time
Software Technologist 2
Philips
Manufactures sleep therapy and respiratory devices
No salary listed
Bengaluru, Karnataka, India
Hybrid
Three days in the office per week are required.
 Software Engineering (1) |
|---|
- Strong understanding of MR imaging principles.
- Expertise in clinical feature development and image quality optimization.
- Ability to translate clinical requirements into software solutions.
- Exposure to advanced imaging techniques, including acceleration methods, full field-of-view imaging, and perfusion imaging.
- Six to ten years of experience in the MR imaging domain.
- Proven experience developing clinical software features, including design, implementation, and validation.
- A solid foundation in software architecture and system design, with the ability to translate clinical needs into scalable solutions.
- Strong programming experience in C++ for performance-critical systems and Python for prototyping and data analysis.
- Experience with imaging algorithms and reconstruction techniques, focused on performance and image quality improvement.
- Understanding of autonomous MR concepts, including adaptive imaging, workflow automation, and intelligent systems.
- Experience with software quality processes, including test automation, continuous integration and continuous delivery, and regulated development environments.
- Strong problem-solving and debugging skills in complex system environments.
- Experience using modern development tools and artificial-intelligence-assisted coding to improve efficiency.
- Ability to collaborate effectively across cross-functional teams and drive technical alignment.
- Lead the design, development, and implementation of advanced clinical software features for Neuro MR solutions.
- Own the end-to-end feature lifecycle, from concept and architecture through validation and release readiness.
- Contribute to yearly clinical releases, such as RSNA, while ensuring alignment with roadmap and timeline commitments.
- Drive innovation through prototyping and early clinical validation studies to improve patient outcomes and workflow efficiency.
- Develop high-level and detailed software designs aligned with system requirements and reference architectures.
- Ensure robust, scalable, and high-quality software implementation in compliance with regulatory and product standards.
- Lead design reviews, failure mode and effects analyses, and technical discussions to ensure quality and risk mitigation.
- Drive improvements in image quality through domain expertise and collaboration with system engineering teams.
- Collaborate with Clinical Science and Clinical Applications teams to refine clinical requirements and validate solutions.
- Work with program teams, system architects, and product management to align feature development with business and customer needs.
- Engage with stakeholders to incorporate clinical feedback, expert testing insights, and customer use cases.
- Leverage advanced tools, including artificial-intelligence-based tooling such as Copilot, to improve development efficiency and debugging effectiveness.
- Contribute to new clinical concepts and future roadmap initiatives, including adaptive imaging and advanced reconstruction techniques.
- Support early-stage solution development and technology exploration aligned with long-term clinical strategy.
- Demonstrated ability to mentor, guide, and influence teams in a non-hierarchical environment.
Philips Respironics designs sleep and respiratory care devices, including CPAP and BiPAP machines, ventilators, and oxygen concentrators, plus related systems. These devices deliver regulated air pressure, support or assist breathing, and provide concentrated oxygen, often paired with software and data tools for monitoring. The division differentiates itself through its long history within Philips and its integrated ecosystem that connects devices with analytics and clinical support across hospital, clinic, and home settings. Its goal is to improve quality of life and clinical outcomes for people with sleep and respiratory conditions by offering reliable devices, patient support, and data-driven care.
Company Size
N/A
Company Stage
Acquired
Total Funding
$164.7M
Headquarters
Murrysville, Pennsylvania
Founded
1891
Simplify's Take
What believers are saying
- Philips reported EUR 17.8 billion 2025 sales and returned to EUR 897 million net income.
- Q1 2026 orders grew 6%, while Philips reiterated 3%-4.5% sales growth and EUR 1.3-1.5 billion cash.
- Ventilator remediation continues in 2026, and 31 countries already closed field-safety actions.
What critics are saying
- The FDA still bars new U.S. CPAP, BiPAP, and respiratory-device sales until compliance.
- June 2025 DreamStation recall shows supplier rework failures still trigger fresh safety interruptions.
- Respironics-related charges reached EUR 209 million in 2025, and DOJ investigations remain excluded from guidance.
What makes Philips unique
- Philips Respironics remains one of few global sleep-therapy platforms with installed-device service scale.
- Its 2026 FDA consent decree preserves accessories, consumables, parts, and medically necessary-device sales.
- More than 99% of recalled CPAP and BiPAP devices were remediated globally by December 2025.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Health Savings Account/Flexible Spending Account
Company News
The global remote patient monitoring market is expected to grow from $67.3 billion in 2026 to $117.9 billion by 2033, registering a CAGR of 8.3%. Growth is driven by rising chronic disease prevalence, expanding telehealth services and increasing demand for home-based healthcare solutions. Devices and hardware account for nearly 38% of market share, led by connected blood pressure monitors, glucometers and wearable health trackers. North America holds approximately 41% of the global market, supported by strong digital healthcare infrastructure and favourable reimbursement policies. Asia Pacific is emerging as the fastest-growing region, driven by healthcare digitisation, telemedicine expansion and rising smartphone penetration. Leading players include Philips Healthcare, Medtronic, GE HealthCare and Abbott Laboratories, focusing on AI integration and cloud connectivity to enhance remote care delivery.
<img src="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp" alt="Philips Respironics Reaches Final Agreement with US Regulators on Sleep Apnea Device Recall. " class="wp-image-78777" srcset="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp 700w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-300x161.webp 300w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-290x155.webp 290w" sizes="(max-width: 700px) 100vw, 700px">What You Should Know: – Philips Respironics, a subsidiary of Royal Philips, has finalized a consent decree with the US Department of Justice (DOJ) and Food and Drug Administration (FDA) to address issues raised during a 2021 inspection of a Philips facility in Pennsylvania.– The agreement focuses on Philips Respironics’ operations in the US, particularly regarding the recall of certain sleep and respiratory care devices.– The company’s focus will now be on completing remediation efforts, ensuring patient safety, and regaining regulatory approval to resume sales of new devices in the US.Focus on Remediation and ComplianceThe consent decree outlines a roadmap for Philips Respironics to:Prioritize Recall Remediation: Philips will continue efforts to remediate millions of sleep apnea and respiratory care devices recalled in June 2021 due to potential health risks associated with degraded sound abatement foam.Independent Oversight: Independent experts will be brought in to review recall remediation efforts and ensure Philips Respironics’ business operations comply with FDA regulations.Continued Patient Support: Philips Respironics can continue servicing existing devices in the hands of patients and healthcare providers. Additionally, they can sell accessories, consumables, and replacement parts for these devices.Sales Restrictions Remain in USThe FDA has not yet authorized Philips Respironics to resume sales of new CPAP, BiPAP, or other respiratory care devices in the US. This restriction will remain in place until Philips meets the requirements outlined in the consent decree.Global Sales Continue with RestrictionsPhilips Respironics can continue to sell new devices, accessories, consumables, and replacement parts outside the US, subject to specific requirements.Safety of Devices with New Foam ConfirmedPhilips Respironics has conducted tests on devices using a new silicone sound abatement foam and found no safety issues. Patients can continue to use these devices following the instructions for use.Financial ImpactPhilips anticipates incurring costs associated with remediation activities and profit disgorgement related to US sales. These costs are estimated at 100 basis points in 2024. The company’s previously announced 2023-2025 financial outlook remains unchanged, already factoring in the consent decree. “Strengthening patient safety and quality remains Philips’ highest priority and the increased scrutiny will help us to improve even more
Following a recall of millions of its breathing machines that began in mid-2021, Phillips Respironics announced Monday that it would halt sales of all such machines within the United States.
In June of 2021, Philips began a recall of over five million of its breathing devices due to toxic fume and substances emanating from the devices’ sound abatement foam.
February 2019 – Koninklijke Philips launched the EPIQ Elite ultrasound system in the market.